UK drugmaker GlaxoSmithKline said on Monday that it has received approval from the US Food and Drug Administration (FDA) to market its five-in-one combination vaccine Pediarix, which could result in 24 million fewer injections per year for US infants.
GlaxoSmithKline said the FDA approved Pediarix for protection against diphtheria, tetanus, pertussis, hepatitis B and polio in infants 2, 4 and 6 months of age, resulting in up to six fewer injections under the current recommended schedule.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!